Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Corneal Epithelial Disorders: early-phase trial registry
1 of 2 indexed Corneal Epithelial Disorders trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Corneal Epithelial Disorders: 2 US clinical trials tracked, 1 recruiting.
Corneal Epithelial Disorders is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Senju Pharmaceutical Co., running 1 of these trials.
Enrollment posture brief
Registry condition corneal-epithelial-disorders
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Corneal Epithelial Disorders lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Corneal Epithelial Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Corneal Epithelial Disorders is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
University of Illinois at Chicago
NCT06919081
Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Senju Pharmaceutical Co.
NCT02104388
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Corneal Epithelial Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Corneal Epithelial Disorders trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Corneal Epithelial Disorders page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Corneal Epithelial Disorders trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Senju Pharmaceutical Co. sponsors the most Corneal Epithelial Disorders trials on record, review their full trial history before evaluating a specific study. See Senju Pharmaceutical Co.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Corneal Epithelial Disorders condition card totals 2 registered trials; most-linked intervention Vehicle of SJP-0035 Ophthalmic Solution; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.